Floating Drug Delivery Systems: An Emerging Trend for the Treatment of Peptic Ulcer

Author(s): Ankit Namdev, Dharmendra Jain*.

Journal Name: Current Drug Delivery

Volume 16 , Issue 10 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Floating drug delivery system (FDDS) is the main approach to prolonging the gastric residence time in the stomach in which the bilayer floating tablet has the main role. It is more suitable for the treatment of local infections such as peptic ulcer, gastritis, Zollinger-Ellision syndrome, indigestion, and other local infections related to the gastrointestinal tract and also used for systemic applications. FDDS provides protection for those drugs which are acid labile and have a short half-life. It also improves bioavailability, reduces drug waste, and enhances the residence time of drugs. Nowadays, various technologies are being used for the development of FDDS. Novel drug delivery systems incorporation into bilayer floating tablets have also broadened the role of FDDS. Polymers have the main role in the development of FDDS, which serve as carriers for the drug and determine the gastric retention time and drug protection. FDDS is also an easy, cheap, and more convenient method for dual drug delivery of drugs.

Keywords: Gastroretentive drug delivery system, Floating Drug Delivery System (FDDS), Bilayer tablet, peptic ulcer, novel drug delivery system, gastrointestinal tract.

[1]
Holton, J. Peptic ulcer disease Essentials of Genomic and Personalized Medicine by Ginsburg GS; Willard HF, 2010, pp. 627-642.
[http://dx.doi.org/10.1016/B978-0-12-374934-5.00049-0]
[2]
Oppong, P.; Majumdar, D.; Atherton, J. Helicobacter pylori infection and peptic ulcers. Medicine (Baltimore), 2015, 43(4), 215-222.
[http://dx.doi.org/10.1016/j.mpmed.2015.01.008]
[3]
Ramakrishnan, K.; Salinas, R.C. Peptic ulcer disease. Am. Fam. Physician, 2007, 76(7), 1005-1012.
[PMID: 17956071]
[4]
Urs, A.N.; Narula, P.; Thomson, M. Peptic ulcer disease. Paediatr. Child Health, 2014, 24, 485-490.
[http://dx.doi.org/10.1016/j.paed.2014.06.003]
[5]
Jones, M.P. The role of psychosocial factors in peptic ulcer disease: Beyond Helicobacter pylori and NSAIDs. J. Psychosom. Res., 2006, 60(4), 407-412.
[http://dx.doi.org/10.1016/j.jpsychores.2005.08.009] [PMID: 16581366]
[6]
Lanas, A.; Chan, F.K.L. Peptic ulcer disease. Lancet, 2017, 390(10094), 613-624.
[http://dx.doi.org/10.1016/S0140-6736(16)32404-7] [PMID: 28242110]
[7]
Rawla, P.; Barsouk, A. Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz. Gastroenterol., 2019, 14(1), 26-38.
[8]
Arora, N.; Majumder, K.; Gupta, A. Gastric cancer and the microbiome. Asian Pac. J. Trop. Dis., 2015, 5, 353-357.
[http://dx.doi.org/10.1016/S2222-1808(14)60796-9]
[9]
Proctor, M.J.; Deans, C. Complications of peptic ulcers. Surgery, 2014, 32, 599-607.
[http://dx.doi.org/10.1016/j.mpsur.2014.09.005]
[10]
Papatheodoridis, G.V.; Sougioultzis, S.; Archimandritis, A.J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: A systematic review. Clin. Gastroenterol. Hepatol., 2006, 4(2), 130-142.
[http://dx.doi.org/10.1016/j.cgh.2005.10.006] [PMID: 16469671]
[11]
Griffin, M.R.; Ray, W.A.; Schaffner, W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann. Intern. Med., 1988, 109(5), 359-363.
[http://dx.doi.org/10.7326/0003-4819-109-5-359] [PMID: 3261560]
[12]
Lanas, A.; Hirschowitz, B.I. Influence of smoking on basal and on vagally and maximally stimulated gastric acid and pepsin secretion. Scand. J. Gastroenterol., 1992, 27(3), 208-212.
[http://dx.doi.org/10.3109/00365529208999950] [PMID: 1502483]
[13]
Boltin, D. Probiotics in Helicobacter pylori-induced peptic ulcer disease. Best Pract. Res. Clin. Gastroenterol., 2016, 30(1), 99-109.
[http://dx.doi.org/10.1016/j.bpg.2015.12.003] [PMID: 27048901]
[14]
Shapla, U.M.; Raihan, J.; Islam, A.; Alam, F.; Solayman, N.; Gan, S.H.; Hossen, S.; Khalil, I. Propolis: The future therapy against Helicobacter pylori-mediated gastrointestinal diseases. J. Appl. Biomed., 2018, 1, 81-99.
[http://dx.doi.org/10.1016/j.jab.2017.10.007]
[15]
Wang, A.Y.; Peura, D.A. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest. Endosc. Clin. N. Am., 2011, 21(4), 613-635.
[http://dx.doi.org/10.1016/j.giec.2011.07.011] [PMID: 21944414]
[16]
Makovec, F.; D’Amato, M. CCKB/gastrin receptor antagonists as potential drugs for peptic ulcer therapy. Drug Discov. Today, 1997, 2, 283-293.
[http://dx.doi.org/10.1016/S1359-6446(97)01044-1]
[17]
Kansara, S.; Sakhreliya, B.D. Peptic ulcer - Its Pathogenesis and Recent Approaches for the Treatment. J. Pharm. Sci. Bio. Res., 2013, 3, 136-144.
[18]
Awaad, A.S.; El-Meligy, R.M.; Soliman, G.A. Natural products in treatment of ulcerative colitis and peptic ulcer. J. Saudi Chem. Soc., 2012, 17, 101-124.
[http://dx.doi.org/10.1016/j.jscs.2012.03.002]
[19]
Tripathi, K.D. Essential of medical Pharmacology, 7th ed; JP Publication: New Delhi, 2015, pp. 647-656.
[20]
Shin, J.M.; Kim, N. Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors. J. Neurogastroenterol. Motil., 2013, 19(1), 25-35.
[http://dx.doi.org/10.5056/jnm.2013.19.1.25]
[21]
Robert, A.; Nezamis, J.E.; Lancaster, C.; Hanchar, A.J. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology, 1979, 77(3), 433-443.
[http://dx.doi.org/10.1016/0016-5085(79)90002-7] [PMID: 456839]
[22]
Petersen, J.M.; Caride, V.J.; Prokop, E.K.; Troncale, F.J.; McCallum, R.W. Sucralfate delays gastric emptying of liquids and solids in duodenal ulcer patients. Int. J. Rad. Appl. Instrum. B, 1989, 16(4), 389-395.
[http://dx.doi.org/10.1016/0883-2897(89)90106-2] [PMID: 2777580]
[23]
Hunt, R.H. Treatment of peptic ulcer disease with sucralfate: A review. Am. J. Med., 1991, 91(2A), 102S-106S.
[http://dx.doi.org/10.1016/0002-9343(91)90459-B] [PMID: 1882894]
[24]
Soll, A.H. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. JAMA, 1996, 275(8), 622-629.
[http://dx.doi.org/10.1001/jama.1996.03530320046033] [PMID: 8594244]
[25]
Sutton, P.; Boag, J.M. Status of vaccine research and development for Helicobacter pylori. Vaccine, 2018, 5, 1-5.
[http://dx.doi.org/10.1016/j.vaccine.2018.01.001] [PMID: 29627231]
[26]
Pinder, R.M.; Brogden, R.N.; Sawyer, P.R.; Speight, T.M.; Spencer, R.; Avery, G.S. Carbenoxolone: A review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs, 1976, 11(4), 245-307.
[http://dx.doi.org/10.2165/00003495-197611040-00002]
[27]
Suvitayavat, W.; Sumrongkit, C.; Thirawarapan, S.S.; Bunyapraphatsara, N. Effects of Aloe preparation on the histamine-induced gastric secretion in rats. J. Ethnopharmacol., 2004, 90(2-3), 239-247.
[http://dx.doi.org/10.1016/j.jep.2003.09.044] [PMID: 15013187]
[28]
Reddy, V.T.; Kumar, S.H.; Bakshi, V. Antiulcer Effect of Formulation of Aloe Vera & Liquorice Against Aspirin Induced Peptic Ulcer. Int. J. App. Pharm. Sci. Res., 2016, 1, 42-45.
[http://dx.doi.org/10.21477/ijapsr.v1i1.10174]
[29]
Harsha, C.; Banik, K.; Bordoloi, D.; Kunnumakkara, A.B. Antiulcer properties of fruits and vegetables: A mechanism based perspective. Food Chem. Toxicol, 2017, 108(Pt A), 104-119.
[http://dx.doi.org/10.1016/j.fct.2017.07.023] [PMID: 28711545]
[30]
Bagheri, S.M.; Zare-Mohazabieh, F.; Momeni-Asl, H.; Yadegari, M.; Mirjalili, A.; Anvari, M. Antiulcer and hepatoprotective effects of aqueous extract of Plantago ovata seed on indomethacin-ulcerated rats. Biomed. J., 2018, 41(1), 41-45.
[http://dx.doi.org/10.1016/j.bj.2018.01.001] [PMID: 29673551]
[31]
da Silva, Junior, I.F.; Balogun, S.O.; de Oliveira, R.G.; Damazo, A.S.; Martins, D.T.O. Piper umbellatum L.: A medicinal plant with gastric-ulcer protective and ulcer healing effects in experimental rodent models. J. Ethnopharmacol., 2016, 192, 123-131.
[http://dx.doi.org/10.1016/j.jep.2016.07.011] [PMID: 27396348]
[32]
Khoder, G.; Al-Menhali, A.A.; Al-Yassir, F.; Karam, S.M. Potential role of probiotics in the management of gastric ulcer. Exp. Ther. Med., 2016, 12(1), 3-17.
[http://dx.doi.org/10.3892/etm.2016.3293] [PMID: 27347010]
[33]
Zhang, M.M.; Qian, W.; Qin, Y.Y.; He, J.; Zhou, Y.H. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J. Gastroenterol., 2015, 21(14), 4345-4357.
[http://dx.doi.org/10.3748/wjg.v21.i14.4345] [PMID: 25892886]
[34]
Wang, F.; Feng, J.; Chen, P.; Liu, X.; Ma, M.; Zhou, R.; Chang, Y.; Liu, J.; Li, J.; Zhao, Q. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin. Res. Hepatol. Gastroenterol., 2017, 41(4), 466-475.
[http://dx.doi.org/10.1016/j.clinre.2017.04.004] [PMID: 28552432]
[35]
Johnston, D.; Wilkinson, A.R. Highly selective vagotomy without a drainage procedure in the treatment of duodenal ulcer. Br. J. Surg., 1970, 57(4), 289-296.
[http://dx.doi.org/10.1002/bjs.1800570414] [PMID: 5437926]
[36]
Singh, B.N.; Kim, K.H. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J. Control. Release, 2000, 63(3), 235-259.
[http://dx.doi.org/10.1016/S0168-3659(99)00204-7] [PMID: 10601721]
[37]
Bardonnet, P.L.; Faivre, V.; Pugh, W.J.; Piffaretti, J.C.; Falson, F. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J. Control. Release, 2006, 111(1-2), 1-18.
[http://dx.doi.org/10.1016/j.jconrel.2005.10.031] [PMID: 16403588]
[38]
Raza, A.; Shen, N.; Li, J.; Chen, Y.; Wang, J-Y. Formulation of zein based compression coated floating tablets for enhanced gastric retention and tunable drug release. Eur. J. Pharm. Sci., 2019, 132, 163-173.
[http://dx.doi.org/10.1016/j.ejps.2019.01.025]
[39]
Patel, A.U.; Caudhari, D.V.; Shah, P.J.; Shah, S.A. Hot melt granulation method for the preparation of floating matrix tablets of Tolperison Hydrochloride. Future J Pharm Sci., 2018, 4, 139-149.
[http://dx.doi.org/10.1016/j.fjps.2017.12.002]
[40]
Chowdary, K.P.R.; Chaitanya, C.H.K.L. Recent research on floating drug delivery systems-a review. J. Glob. Trends Pharm. Sci., 2014, 5, 1361-1373.
[41]
Kaur, B. Sharma, S.; Sharma, G.; Saini, R.; Singh, S.; Nagpal, M.; Jain, U.K.; Sharma, M. A Review of Floating Drug Delivery System. Asian J Biomed Pharm Sci., 2013, 3, 1-6.
[42]
Devtalu, S.V.; Patil, A.E.; Bari, M.M.; Barhate, S.D. A review on novel approach-bi-layer tablet technology. Int. J. Pharm. Sci. Rev. Res., 2013, 21, 46-52.
[43]
Deshpande, R.D.; Gowda, D.V.; Mahammed, N.; Deepak, N. Bi-layer tablets-an emerging trend: A review. Int. J. Pharm. Sci. Res., 2011, 2, 2534-2544.
[44]
Pujara, N.D.; Gokani, R.K.; Paun, J.S. Bilayer tablet-an emerging trend. Int. J. Phar. Res. Dev., 2012, 4, 102-111.
[45]
Das, S.R.; Panigrahi, B.B.; Pani, M.K. A review: On bilayer floating tablet as multifunctional approach of gastroretentive drug delivery system. Int. J. Recent Scientific Res, , 10, 06(H), 33255- 33267.
[http://dx.doi.org/10.24327/IJRSR]
[46]
Abebe, A.; Akseli, I.; Sprockel, O.; Kottala, N.; Cuitiño, A.M. Review of bilayer tablet technology. Int. J. Pharm., 2014, 461(1-2), 549-558.
[http://dx.doi.org/10.1016/j.ijpharm.2013.12.028] [PMID: 24370841]
[47]
Lende, L.K.; Banerjee, S.K.; Gadhave, M.V. Review on: Bilayer floating tablet. Asian J. Pharm. Res. Dev., 2013, 1, 31-39.
[48]
Prajapati, V.D.; Jani, G.K.; Khutliwala, T.A.; Zala, B.S. Raft forming system-an upcoming approach of gastroretentive drug delivery system. J. Control. Release, 2013, 168(2), 151-165.
[http://dx.doi.org/10.1016/j.jconrel.2013.02.028] [PMID: 23500062]
[49]
Arora, S.; Ali, J.; Ahuja, A.; Khar, R.K.; Baboota, S. Floating drug delivery systems: A review. AAPS PharmSciTech, 2005, 6(3), E372-E390.
[http://dx.doi.org/10.1208/pt060347] [PMID: 16353995]
[50]
Singh, A.K.; Dubey, V.; Arora, V. Role of natural polymers used in floating drug delivery system. J Pharm Sci Inno., 2012, 1, 11-15.
[51]
Muxika, A.; Etxabide, A.; Uranga, J.; Guerrero, P.; de la Caba, K. Chitosan as a bioactive polymer: Processing, properties and applications. Int. J. Biol. Macromol., 2017, 105(Pt 2), 1358-1368.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.07.087] [PMID: 28735006]
[52]
Jain, D.; Bar-Shalom, D. Alginate drug delivery systems: Application in context of pharmaceutical and biomedical research. Drug Dev. Ind. Pharm., 2014, 40(12), 1576-1584.
[http://dx.doi.org/10.3109/03639045.2014.917657] [PMID: 25109399]
[53]
Lara-Espinoza, C.; Carvajal-Millán, E.; Balandrán-Quintana, R.; López-Franco, Y.; Rascón-Chu, A. Pectin and Pectin-Based Composite Materials: Beyond Food Texture. Molecules. , 2018 18;23(4). pii: E942.
[http://dx.doi.org/10.3390/molecules23040942]
[54]
Swapna, B.D.; Abhinay, D. Formulation and evaluation of bilayer tablets of salbutamol sulphate and cetirizine for the treatment of asthma. World J. Pharm. Pharm. Sci., 2014, 3, 1144-1157.
[55]
Chaurasia, V.; Kumar, V.; Jain, D. Sumatriptan succinate loaded microspheres containing compressed core tablets for effective treatment of migraine. Bull Pharm. Res., 2016, 6, 56-67.
[http://dx.doi.org/10.21276/bpr.2016.6.2.4]
[56]
Logidhasan, L.; Suresh, S.; Mathivanan, M. Formulation and in vitro evaluation of bilayer floating tablets of Aceclofenac and Ranitidine HCl. Int. Res. J. Pharm. App. Sci., 2013, 3, 88-94.
[57]
Pethkar, S.V.; Suggala, V.; Gholap, S. Review on: Bilayer floating tablet. World J. Pharm. Pharm. Sci., 2016, 5, 1411-1423.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 10
Year: 2019
Page: [874 - 886]
Pages: 13
DOI: 10.2174/1567201816666191018163519
Price: $65

Article Metrics

PDF: 28
HTML: 1

Special-new-year-discount